| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 17.55M | 21.15M | 14.28M | 21.34M | 17.98M | 22.77M | 54.22M |
| Revenue Growth % | - | 0.2% | -0.32% | 0.49% | -0.16% | 0.27% | 1.38% |
| Cost of Goods Sold | 6.55M | 6.32M | 4.93M | 9.65M | 19.66M | 16.02M | 14.99M |
| COGS % of Revenue | 0.37% | 0.3% | 0.35% | 0.45% | 1.09% | 0.7% | 0.28% |
| Gross Profit | 11M | 14.82M | 9.35M | 11.68M | -1.69M | 6.75M | 39.23M |
| Gross Margin % | 0.63% | 0.7% | 0.65% | 0.55% | -0.09% | 0.3% | 0.72% |
| Gross Profit Growth % | - | 0.35% | -0.37% | 0.25% | -1.14% | 5% | 4.81% |
| Operating Expenses | 1.1K | 278.95M | 161.27M | 120.74M | 23.91M | 199.04M | 77.59M |
| OpEx % of Revenue | 0% | 13.19% | 11.3% | 5.66% | 1.33% | 8.74% | 1.43% |
| Selling, General & Admin | 1.1K | 41.79M | 31.34M | 71.34M | 66.02M | 50.58M | 58.64M |
| SG&A % of Revenue | 0% | 1.98% | 2.19% | 3.34% | 3.67% | 2.22% | 1.08% |
| Research & Development | 29.06M | 46.05M | 52.71M | 88.35M | 78.36M | 30.46M | 17.39M |
| R&D % of Revenue | 1.66% | 2.18% | 3.69% | 4.14% | 4.36% | 1.34% | 0.32% |
| Other Operating Expenses | -31.6M | 191.11M | 77.23M | -38.95M | -120.47M | 118M | 1.56M |
| Operating Income | -1.1K | -264.13M | -151.93M | -109.06M | -25.6M | -192.29M | -38.36M |
| Operating Margin % | -0% | -12.49% | -10.64% | -5.11% | -1.42% | -8.44% | -0.71% |
| Operating Income Growth % | - | -240553.64% | 0.42% | 0.28% | 0.77% | -6.51% | 0.8% |
| EBITDA | 4.79M | -257.94M | -143.75M | -100.24M | -16.16M | -182.96M | -30.44M |
| EBITDA Margin % | 0.27% | -12.2% | -10.07% | -4.7% | -0.9% | -8.03% | -0.56% |
| EBITDA Growth % | - | -54.86% | 0.44% | 0.3% | 0.84% | -10.32% | 0.83% |
| D&A (Non-Cash Add-back) | 4.79M | 6.19M | 8.17M | 8.82M | 9.44M | 9.32M | 7.92M |
| EBIT | -1.1K | -77.16M | -210.58M | -96.93M | -148.27M | -193.27M | -51.63M |
| Net Interest Income | 0 | 694K | -1.98M | -2.84M | 365K | -2.69M | -5.93M |
| Interest Income | 628K | 694K | 370K | 332K | 365K | 320K | 331K |
| Interest Expense | 0 | 0 | 2.35M | 3.17M | 0 | 3.02M | 6.26M |
| Other Income/Expense | 2 | -3.87M | -61.01M | 8.96M | 39.8M | -4M | -19.53M |
| Pretax Income | -1.1K | -267.99M | -212.93M | -100.1M | 14.21M | -196.28M | -57.89M |
| Pretax Margin % | -0% | -12.67% | -14.91% | -4.69% | 0.79% | -8.62% | -1.07% |
| Income Tax | 0 | -56.11M | -4.7M | 20K | 13K | 10K | 0 |
| Effective Tax Rate % | 1% | 0.79% | 0.98% | 1% | 1% | 1% | 1% |
| Net Income | -1.1K | -211.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M |
| Net Margin % | -0% | -10.02% | -14.58% | -4.69% | 0.79% | -8.62% | -1.07% |
| Net Income Growth % | - | -192968.95% | 0.02% | 0.52% | 1.14% | -14.83% | 0.71% |
| Net Income (Continuing) | -1.1K | -211.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | -88.75 | -113.06 | -14.93 | 0.95 | -11.02 | -2.64 |
| EPS Growth % | - | - | -0.27% | 0.87% | 1.06% | -12.63% | 0.76% |
| EPS (Basic) | 0.00 | -88.75 | -113.06 | -14.93 | 1.01 | -11.02 | -2.64 |
| Diluted Shares Outstanding | 3.59M | 2.39M | 1.84M | 6.71M | 14.98M | 17.81M | 21.89M |
| Basic Shares Outstanding | 3.59M | 2.39M | 1.84M | 6.71M | 13.99M | 17.81M | 21.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.71K | 36.81M | 72.16M | 59.1M | 33.5M | 19.79M | 20.56M |
| Cash & Short-Term Investments | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K |
| Cash Only | 24.71K | 28.13M | 54.31M | 37.24M | 13.97M | 227K | 738K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3.92M | 3.08M | 6.55M | 5.23M | 6.97M | 12.12M | 13.56M |
| Days Sales Outstanding | 81.49 | 53.13 | 167.44 | 89.53 | 141.45 | 194.24 | 91.26 |
| Inventory | 3.54M | 3.23M | 3.85M | 9.55M | 5.31M | 5.75M | 5.41M |
| Days Inventory Outstanding | 196.89 | 186.54 | 284.93 | 361.07 | 98.52 | 131.11 | 131.72 |
| Other Current Assets | 1.49M | 480K | 873K | 2K | 1.05M | 0 | 857K |
| Total Non-Current Assets | 532.17M | 484.69M | 358.85M | 355.03M | 367.56M | 124.1M | 112.12M |
| Property, Plant & Equipment | 4.01M | 66.39M | 90.08M | 90.63M | 88.72M | 78.82M | 72.43M |
| Fixed Asset Turnover | 4.38x | 0.32x | 0.16x | 0.24x | 0.20x | 0.29x | 0.75x |
| Goodwill | 130.64M | 127.07M | 123.3M | 123.3M | 119.69M | 7.35M | 7.35M |
| Intangible Assets | 393.71M | 271.47M | 125.38M | 123.19M | 120.99M | 11M | 9.25M |
| Long-Term Investments | 0 | 291M | 15.2M | 14.84M | 14.84M | 9.94M | 10.24M |
| Other Non-Current Assets | 3.81M | -271.24M | 4.89M | 3.08M | 23.32M | 26.93M | 12.86M |
| Total Assets | 24.71K | 521.5M | 431.01M | 414.13M | 401.07M | 143.89M | 132.68M |
| Asset Turnover | 710.49x | 0.04x | 0.03x | 0.05x | 0.04x | 0.16x | 0.41x |
| Asset Growth % | - | 21106.18% | -0.17% | -0.04% | -0.03% | -0.64% | -0.08% |
| Total Current Liabilities | 150.56K | 20.64M | 26.68M | 26.23M | 62.09M | 67.3M | 53.68M |
| Accounts Payable | 5.27M | 18.88K | 5.39M | 9.32M | 5.81M | 14.14M | 23.3M |
| Days Payables Outstanding | 293.34 | 1.09 | 398.89 | 352.3 | 107.84 | 322.34 | 567.29 |
| Short-Term Debt | 0 | 0 | 3.01M | 3.05M | 37.6M | 39.24M | 6.36M |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | -10.74M | 11.23M | 8.17M | 7.83M | 13.83M | 8.07M | 1.6M |
| Current Ratio | 0.16x | 1.78x | 2.70x | 2.25x | 0.54x | 0.29x | 0.38x |
| Quick Ratio | -23.32x | 1.63x | 2.56x | 1.89x | 0.45x | 0.21x | 0.28x |
| Cash Conversion Cycle | -14.95 | 238.58 | 53.47 | 98.3 | 132.13 | 3.01 | -344.31 |
| Total Non-Current Liabilities | 0 | 363M | 385.62M | 288.48M | 140.08M | 35.63M | 70.17M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 35.93M |
| Capital Lease Obligations | 0 | 28.06M | 27.63M | 28.09M | 27.98M | 26.18M | 26.55M |
| Deferred Tax Liabilities | 0 | 0 | 7K | 10K | 9K | 9K | 9K |
| Other Non-Current Liabilities | 0 | 334.94M | 350.36M | 258.52M | 109.86M | 6.26M | 4.96M |
| Total Liabilities | 150.56K | 383.63M | 412.3M | 314.71M | 202.16M | 102.93M | 123.84M |
| Total Debt | 150K | 28.06M | 30.64M | 31.14M | 65.59M | 65.42M | 68.84M |
| Net Debt | 125.29K | -66K | -23.67M | -6.1M | 51.62M | 65.19M | 68.1M |
| Debt / Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x |
| Debt / EBITDA | 0.03x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.03x | - | - | - | - | - | - |
| Interest Coverage | - | - | -64.54x | -34.39x | - | -63.78x | -6.12x |
| Total Equity | -125.85K | 137.86M | 18.71M | 99.42M | 198.9M | 40.96M | 8.84M |
| Equity Growth % | - | 1096.47% | -0.86% | 4.31% | 1% | -0.79% | -0.78% |
| Book Value per Share | -0.04 | 57.75 | 10.16 | 14.83 | 13.28 | 2.30 | 0.40 |
| Total Shareholders' Equity | -125.85K | 137.86M | 18.71M | 99.42M | 198.9M | 40.96M | 8.84M |
| Common Stock | 863 | 1K | 1K | 12K | 15K | 19K | 2K |
| Retained Earnings | -1.1K | -355.33M | -563.56M | -663.68M | -645.5M | -841.79M | -899.68M |
| Treasury Stock | 0 | 0 | -256K | 0 | 0 | 0 | 0 |
| Accumulated OCI | -149.75K | 0 | 0 | 0 | 9K | 0 | -5K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -543 | -1.1M | -63.19M | -110.1M | -137.88M | -38.69M | -6.4M |
| Operating CF Margin % | -0% | -0.05% | -4.43% | -5.16% | -7.67% | -1.7% | -0.12% |
| Operating CF Growth % | - | -2020.79% | -56.56% | -0.74% | -0.25% | 0.72% | 0.83% |
| Net Income | -13.38M | 5.88M | -208.23M | -100.12M | 14.19M | -196.29M | -57.89M |
| Depreciation & Amortization | 4.79M | 0 | 8.17M | 8.82M | 9.44M | 11.47M | 7.92M |
| Stock-Based Compensation | 4.5M | 0 | 4.37M | 40.01M | 15.86M | 15.02M | 11.57M |
| Deferred Taxes | 0 | -1.65K | -8.48M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -54.54M | -7.11M | 137.37M | -53.1M | -161.91M | 137.89M | 9.8M |
| Working Capital Changes | -1.34M | 136.39K | 3.6M | -5.71M | -15.45M | -6.77M | 22.2M |
| Change in Receivables | -2.29M | 0 | 1.65M | -1.91M | -3.58M | -6.83M | -3.97M |
| Change in Inventory | -3.4M | 0 | -643K | -6.42M | -16.89M | -865K | 6.28M |
| Change in Payables | 0 | 18.88K | 314K | 0 | 0 | 0 | 9.24M |
| Cash from Investing | -31.18M | -286.85M | -12.81M | -5.9M | -5.24M | -4.05M | 514K |
| Capital Expenditures | -1.92M | 0 | -27.83M | -6.2M | -5.24M | -4.05M | -161K |
| CapEx % of Revenue | 0.11% | 0% | 1.95% | 0.29% | 0.29% | 0.18% | 0% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 14K | 651K | 0 | 300K | 0 | 0 | 2.17M |
| Cash from Financing | 25.25K | 288.84M | 102.01M | 98.56M | 119.84M | 24.09M | 6.7M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 250 | 0 | -265K | 97.92M | 27.26M | 7.35M | -459K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -1.92M | -1.1M | -91.03M | -116.3M | -143.11M | -42.73M | -6.56M |
| FCF Margin % | -0.11% | -0.05% | -6.38% | -5.45% | -7.96% | -1.88% | -0.12% |
| FCF Growth % | - | 0.43% | -81.92% | -0.28% | -0.23% | 0.7% | 0.85% |
| FCF per Share | -0.53 | -0.46 | -49.42 | -17.34 | -9.55 | -2.40 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x |
| Interest Paid | 0 | 0 | 0 | 146K | 0 | 1.07M | 144K |
| Taxes Paid | 0 | 0 | 13K | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -307.66% | -265.99% | -169.5% | 9.51% | -163.67% | -232.51% |
| Return on Invested Capital (ROIC) | - | -287.52% | -171.55% | -185.14% | -11.17% | -80.87% | -31.43% |
| Gross Margin | 62.66% | 70.09% | 65.46% | 54.76% | -9.4% | 29.66% | 72.36% |
| Net Margin | -0.01% | -1001.94% | -1458.42% | -469.27% | 78.95% | -862.04% | -106.77% |
| Debt / Equity | - | 0.20x | 1.64x | 0.31x | 0.33x | 1.60x | 7.79x |
| Interest Coverage | - | - | -64.54x | -34.39x | - | -63.78x | -6.12x |
| FCF Conversion | 0.49x | 0.01x | 0.30x | 1.10x | -9.72x | 0.20x | 0.11x |
| Revenue Growth | - | 20.47% | -32.48% | 49.43% | -15.75% | 26.68% | 138.11% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Product | 3.8M | 3.75M | 13.15M | 35.34M |
| Product Growth | - | -1.37% | 250.73% | 168.74% |
| License Royalty and Other | - | - | - | 13.74M |
| License Royalty and Other Growth | - | - | - | - |
| Service | 5.52M | 5.51M | 5.44M | 5.14M |
| Service Growth | - | -0.18% | -1.29% | -5.53% |
| License Royalty And Other | 12.01M | 8.71M | 5.74M | - |
| License Royalty And Other Growth | - | -27.46% | -34.15% | - |
Celularity Inc. (CELU) reported $40.6M in revenue for fiscal year 2024. This represents a 131% increase from $17.6M in 2018.
Celularity Inc. (CELU) grew revenue by 138.1% over the past year. This is strong growth.
Celularity Inc. (CELU) reported a net loss of $80.6M for fiscal year 2024.
Celularity Inc. (CELU) has a return on equity (ROE) of -232.5%. Negative ROE indicates the company is unprofitable.
Celularity Inc. (CELU) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.